- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Secondary Progressive Multiple Sclerosis Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Secondary Progressive Multiple Sclerosis Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Secondary Progressive Multiple Sclerosis Drug market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Secondary Progressive Multiple Sclerosis Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Inebilizumab
GLX-1112
DC-TAB
Etomoxir
IB-MS
Others
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Secondary Progressive Multiple Sclerosis Drug market are listed below:
AB Science SA
Actelion Ltd
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co., Ltd.
Mallinckrodt Plc
MedDay SA
MedImmune, LLC
Merck KGaA
Meta-IQ ApS
Novartis AG
Opexa Therapeutics, Inc.
Xenetic Biosciences (UK) Limited
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Secondary Progressive Multiple Sclerosis Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Secondary Progressive Multiple Sclerosis Drug, with price, sales, revenue and global market share of Secondary Progressive Multiple Sclerosis Drug from 2019 to 2021.
Chapter 3, the Secondary Progressive Multiple Sclerosis Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Secondary Progressive Multiple Sclerosis Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Secondary Progressive Multiple Sclerosis Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Secondary Progressive Multiple Sclerosis Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Secondary Progressive Multiple Sclerosis Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Inebilizumab
1.2.3 GLX-1112
1.2.4 DC-TAB
1.2.5 Etomoxir
1.2.6 IB-MS
1.2.7 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Secondary Progressive Multiple Sclerosis Drug Market Size & Forecast
1.4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Value (2016-2026))
1.4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume (2016-2026)
1.4.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Secondary Progressive Multiple Sclerosis Drug Production Capacity Analysis
1.5.1 Global Secondary Progressive Multiple Sclerosis Drug Total Production Capacity (2016-2026)
1.5.2 Global Secondary Progressive Multiple Sclerosis Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Secondary Progressive Multiple Sclerosis Drug Market Drivers
1.6.2 Secondary Progressive Multiple Sclerosis Drug Market Restraints
1.6.3 Secondary Progressive Multiple Sclerosis Drug Trends Analysis
2 Manufacturers Profiles
2.1 AB Science SA
2.1.1 AB Science SA Details
2.1.2 AB Science SA Major Business
2.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product and Services
2.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Actelion Ltd
2.2.1 Actelion Ltd Details
2.2.2 Actelion Ltd Major Business
2.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product and Services
2.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Biogen, Inc.
2.3.1 Biogen, Inc. Details
2.3.2 Biogen, Inc. Major Business
2.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
2.3.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 F. Hoffmann-La Roche Ltd.
2.4.1 F. Hoffmann-La Roche Ltd. Details
2.4.2 F. Hoffmann-La Roche Ltd. Major Business
2.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product and Services
2.4.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Genzyme Corporation
2.5.1 Genzyme Corporation Details
2.5.2 Genzyme Corporation Major Business
2.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product and Services
2.5.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Glialogix, Inc.
2.6.1 Glialogix, Inc. Details
2.6.2 Glialogix, Inc. Major Business
2.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
2.6.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Immune Response BioPharma, Inc.
2.7.1 Immune Response BioPharma, Inc. Details
2.7.2 Immune Response BioPharma, Inc. Major Business
2.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
2.7.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Innate Immunotherapeutics Ltd
2.8.1 Innate Immunotherapeutics Ltd Details
2.8.2 Innate Immunotherapeutics Ltd Major Business
2.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product and Services
2.8.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Kyorin Pharmaceutical Co., Ltd.
2.9.1 Kyorin Pharmaceutical Co., Ltd. Details
2.9.2 Kyorin Pharmaceutical Co., Ltd. Major Business
2.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product and Services
2.9.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Mallinckrodt Plc
2.10.1 Mallinckrodt Plc Details
2.10.2 Mallinckrodt Plc Major Business
2.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product and Services
2.10.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 MedDay SA
2.11.1 MedDay SA Details
2.11.2 MedDay SA Major Business
2.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product and Services
2.11.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 MedImmune, LLC
2.12.1 MedImmune, LLC Details
2.12.2 MedImmune, LLC Major Business
2.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product and Services
2.12.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.13 Merck KGaA
2.13.1 Merck KGaA Details
2.13.2 Merck KGaA Major Business
2.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product and Services
2.13.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.14 Meta-IQ ApS
2.14.1 Meta-IQ ApS Details
2.14.2 Meta-IQ ApS Major Business
2.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product and Services
2.14.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.15 Novartis AG
2.15.1 Novartis AG Details
2.15.2 Novartis AG Major Business
2.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product and Services
2.15.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.16 Opexa Therapeutics, Inc.
2.16.1 Opexa Therapeutics, Inc. Details
2.16.2 Opexa Therapeutics, Inc. Major Business
2.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
2.16.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.17 Xenetic Biosciences (UK) Limited
2.17.1 Xenetic Biosciences (UK) Limited Details
2.17.2 Xenetic Biosciences (UK) Limited Major Business
2.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product and Services
2.17.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturer
3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Secondary Progressive Multiple Sclerosis Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Secondary Progressive Multiple Sclerosis Drug Manufacturer Market Share
3.4.2 Top 6 Secondary Progressive Multiple Sclerosis Drug Manufacturer Market Share
3.5 Global Secondary Progressive Multiple Sclerosis Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Secondary Progressive Multiple Sclerosis Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Region
4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2016-2026)
4.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026)
4.3 Europe Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026)
4.4 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026)
4.5 South America Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026)
4.6 Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Type (2016-2026)
5.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2016-2026)
5.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Application (2016-2026)
6.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2016-2026)
6.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2026)
7.2 North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2026)
7.3 North America Secondary Progressive Multiple Sclerosis Drug Market Size by Country
7.3.1 North America Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2026)
8.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2026)
8.3 Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Country
8.3.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Market Size by Region
9.3.1 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2026)
10.2 South America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2026)
10.3 South America Secondary Progressive Multiple Sclerosis Drug Market Size by Country
10.3.1 South America Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Market Size by Country
11.3.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Secondary Progressive Multiple Sclerosis Drug Typical Distributors
12.3 Secondary Progressive Multiple Sclerosis Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application, (USD Million), 2021-2026
Table 3. AB Science SA Basic Information, Manufacturing Base and Competitors
Table 4. AB Science SA Major Business
Table 5. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 6. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Actelion Ltd Basic Information, Manufacturing Base and Competitors
Table 8. Actelion Ltd Major Business
Table 9. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 10. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Biogen, Inc. Basic Information, Manufacturing Base and Competitors
Table 12. Biogen, Inc. Major Business
Table 13. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 14. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. F. Hoffmann-La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 16. F. Hoffmann-La Roche Ltd. Major Business
Table 17. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 18. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Genzyme Corporation Basic Information, Manufacturing Base and Competitors
Table 20. Genzyme Corporation Major Business
Table 21. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 22. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Glialogix, Inc. Basic Information, Manufacturing Base and Competitors
Table 24. Glialogix, Inc. Major Business
Table 25. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 26. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Immune Response BioPharma, Inc. Basic Information, Manufacturing Base and Competitors
Table 28. Immune Response BioPharma, Inc. Major Business
Table 29. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 30. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Innate Immunotherapeutics Ltd Basic Information, Manufacturing Base and Competitors
Table 32. Innate Immunotherapeutics Ltd Major Business
Table 33. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 34. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Kyorin Pharmaceutical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 36. Kyorin Pharmaceutical Co., Ltd. Major Business
Table 37. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 38. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Mallinckrodt Plc Basic Information, Manufacturing Base and Competitors
Table 40. Mallinckrodt Plc Major Business
Table 41. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 42. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. MedDay SA Basic Information, Manufacturing Base and Competitors
Table 44. MedDay SA Major Business
Table 45. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 46. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. MedImmune, LLC Basic Information, Manufacturing Base and Competitors
Table 48. MedImmune, LLC Major Business
Table 49. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 50. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Merck KGaA Basic Information, Manufacturing Base and Competitors
Table 52. Merck KGaA Major Business
Table 53. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 54. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Meta-IQ ApS Basic Information, Manufacturing Base and Competitors
Table 56. Meta-IQ ApS Major Business
Table 57. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 58. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 60. Novartis AG Major Business
Table 61. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 62. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 63. Opexa Therapeutics, Inc. Basic Information, Manufacturing Base and Competitors
Table 64. Opexa Therapeutics, Inc. Major Business
Table 65. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 66. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 67. Xenetic Biosciences (UK) Limited Basic Information, Manufacturing Base and Competitors
Table 68. Xenetic Biosciences (UK) Limited Major Business
Table 69. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product and Services
Table 70. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 71. Global Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 72. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 73. Market Position of Manufacturers in Secondary Progressive Multiple Sclerosis Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 74. Global Secondary Progressive Multiple Sclerosis Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 75. Head Office and Secondary Progressive Multiple Sclerosis Drug Production Site of Key Manufacturer
Table 76. Secondary Progressive Multiple Sclerosis Drug New Entrant and Capacity Expansion Plans
Table 77. Secondary Progressive Multiple Sclerosis Drug Mergers & Acquisitions in the Past Five Years
Table 78. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2016-2021e) & (K Pcs)
Table 79. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (K Pcs)
Table 80. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2016-2021e) & (USD Million)
Table 81. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2021-2026) & (USD Million)
Table 82. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 83. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 84. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2016-2021e) & (USD Million)
Table 85. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (USD Million)
Table 86. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 87. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2026) & (USD/Pcs)
Table 88. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 89. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 90. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2016-2021e) & (USD Million)
Table 91. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (USD Million)
Table 92. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 93. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2026) & (USD/Pcs)
Table 94. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 95. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 96. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 97. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 98. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 99. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 100. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 101. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 102. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 103. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 104. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 105. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 106. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 107. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 108. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 109. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 110. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2016-2021e) & (K Pcs)
Table 111. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (K Pcs)
Table 112. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2016-2021e) & (USD Million)
Table 113. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2021-2026) & (USD Million)
Table 114. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 115. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 116. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 117. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 118. South America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 119. South America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 120. South America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 121. South America Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 122. South America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 123. South America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 124. South America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 125. South America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 126. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2016-2021e) & (K Pcs)
Table 127. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Pcs)
Table 128. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2016-2021e) & (USD Million)
Table 129. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2021-2026) & (USD Million)
Table 130. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2016-2021e) & (K Pcs)
Table 131. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Pcs)
Table 132. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2016-2021e) & (K Pcs)
Table 133. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Pcs)
Table 134. Direct Channel Pros & Cons
Table 135. Indirect Channel Pros & Cons
Table 136. Secondary Progressive Multiple Sclerosis Drug Typical Distributors
Table 137. Secondary Progressive Multiple Sclerosis Drug Typical Customers
List of Figures
Figure 1. Secondary Progressive Multiple Sclerosis Drug Picture
Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2020
Figure 3. Inebilizumab
Figure 4. GLX-1112
Figure 5. DC-TAB
Figure 6. Etomoxir
Figure 7. IB-MS
Figure 8. Others
Figure 9. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application in 2020
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Others
Figure 13. Global Secondary Progressive Multiple Sclerosis Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 14. Global Secondary Progressive Multiple Sclerosis Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Sales (2016-2026) & (K Pcs)
Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Production Capacity (2016-2026) & (K Pcs)
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Secondary Progressive Multiple Sclerosis Drug Market Drivers
Figure 20. Secondary Progressive Multiple Sclerosis Drug Market Restraints
Figure 21. Secondary Progressive Multiple Sclerosis Drug Market Trends
Figure 22. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturer in 2020
Figure 23. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Manufacturer in 2020
Figure 24. Secondary Progressive Multiple Sclerosis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Secondary Progressive Multiple Sclerosis Drug Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Secondary Progressive Multiple Sclerosis Drug Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2026)
Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2016-2026)
Figure 29. North America Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 30. Europe Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 32. South America Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue (2016-2026) & (USD Million)
Figure 34. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2026)
Figure 35. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2016-2026)
Figure 36. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 37. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2026)
Figure 38. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2016-2026)
Figure 39. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 40. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2026)
Figure 41. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2026)
Figure 42. North America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2026)
Figure 43. North America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 44. United States Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2026)
Figure 48. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2026)
Figure 49. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2026)
Figure 50. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 51. Germany Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2016-2026)
Figure 60. China Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2026)
Figure 67. South America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2026)
Figure 68. South America Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2026)
Figure 69. South America Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Secondary Progressive Multiple Sclerosis Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
